Nine times out of ten, metastasis is the cause of cancer deaths. This is the point when the primary tumour has sent out cells, like seeds, and invaded other organs of the body. Despite significant advancements in the treatment of primary tumours, medicine remains mainly powerless against metastases. As of right now, there are no drugs that stop this process.
Researchers from the Department of Biosystems Science and Engineering at ETH Zurich in Basel, under the direction of Andreas Moor, have now published findings in the journal Nature that demonstrate how colorectal cancer cells colonise the liver. Their research will aid in the creation of therapies that might impede the spread of disease.
Cancer is said to metastasise when cells from the primary tumour break off and travel via the circulatory system to other parts of the body.
“Colorectal cancer metastasises to the liver because of how our blood flows,” Moor says. Blood is first enriched with nutrients in the intestines before it goes to the liver, which metabolises the nutrients. For colorectal cancer cells, the liver is the last stop. “They get caught in the liver’s capillary network,” Moor says.
Costanza Borrelli, a doctoral student, and other members of Moor’s team have now shown that the liver cells also play a large role in whether or not the cancer cells lodged there can colonise their new location. Science has known for over a century that, much like plant seeds in soil, cancer cells are dependent on their environment, yet it was previously unknown which molecular mechanisms play a role here.
Using sophisticated tests on genetically modified mice, Moor and his team have discovered that the secret lies in certain proteins on the cell surface. When liver cells have a protein called Plexin-B2 and the colorectal cancer cells possess certain proteins from the semaphorin family, the colorectal cancer cells can attach themselves to the liver cells.
Cancer cells that have semaphorins on their surface are especially dangerous, as attested by clinical studies cited by Moor’s researchers in their paper. The study data shows that colorectal cancer metastasises earlier and more frequently to the liver if the tumour has large amounts of semaphorin.
Plexin and its counterpart semaphorin were previously known to the research community for their function in the nervous system, where the two proteins steer growing nerve cells and ensure they form the right pathways. “Why liver cells also create plexin and what this protein does in healthy livers is anything but clear – and interests us immensely,” Moor says. In other words, the question of its function remains open.
What Moor and his team have discovered, however, is that direct contact between plexin and semaphorin triggers fundamental changes in colorectal cancer cells. To break off from the primary tumour, the cancer cells have to change their identity: they free themselves from the surface layer of the intestine, or epithelium, severing their close connections to neighbouring cells.
Once in the bloodstream, the cancer cells resemble those from connective tissue called mesenchyme. Yet once they find their new niche – thanks to the plexin on some liver cells – the cancer cells turn back into their sedentary form. “An epithelisation process takes place,” the researchers wrote in their paper. Moor expands: “You can spot this immediately if you look at the cancer cells, as they form invaginations similar to the folds or crypts in the intestines.”
The researchers’ discovery will have an impact on more than colorectal cancer patients: further tests have shown that plexin also encourages the formation of metastases in melanoma and pancreatic cancer. For Moor and his team, this throws up many new research questions. One in particular is drawing their focus: when cancer cells cluster together to form a tumour, they also influence cells in their environment. “Cancer cells set up their own ecosystem,” Moor explains.
If efforts to inhibit the crucial interaction between plexin and semaphorin succeed, it may be possible to prevent the cancer from establishing new tumours in the first place. That’s because early on, when the relationships among the cells in this ecosystem have not yet been firmly established, tumour metastases are especially vulnerable, Moor explains. He appears confident that an answer lies within this “critical period of time in the development of metastases”, even though the path to any potential treatment is still long.
(with inputs from ANI)
